Comparative Pharmacology
Head-to-head clinical analysis: LAZCLUZE versus SPRX 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZCLUZE versus SPRX 105.
LAZCLUZE vs SPRX-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
20 mg orally once daily with or without food.
SPRX-105 is administered orally at a dose of 50 mg once daily.
None Documented
None Documented
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Category C
Category C
Unknown
Unknown